![](https://library.celltelligence.com/wp-content/uploads/2022/10/Screenshot-2022-10-21-at-17.06.28.png)
$0
Thoughts on Kite’s Licensing Agreement with Refuge Biotechnologies
On Thursday, October 20, Gilead (Kite) announced (press release) that it has entered into a WW license agreement with Refuge Biotechnologies. Of note, Kite will have exclusive rights to utilize Refuge’s proprietary gene expression platform for the development of CAR-Ts in blood cancers. Below, Celltelligence provides insights on Refuge’s synthetic biology technology, while discussing Gilead’s licensing strategy.